Clinical Trial Update: S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer [Phase 3]

View source ↗

Summary

SWOG's Phase 3 trial comparing gemcitabine with or without cetuximab as first-line therapy for locally advanced pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• Gemzar (gemcitabine)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Pancreatic Cancer | Phase 3 | Status: COMPLETED